Nothing Special   »   [go: up one dir, main page]

CY1120115T1 - Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων - Google Patents

Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων

Info

Publication number
CY1120115T1
CY1120115T1 CY20181100378T CY181100378T CY1120115T1 CY 1120115 T1 CY1120115 T1 CY 1120115T1 CY 20181100378 T CY20181100378 T CY 20181100378T CY 181100378 T CY181100378 T CY 181100378T CY 1120115 T1 CY1120115 T1 CY 1120115T1
Authority
CY
Cyprus
Prior art keywords
mesenchymal stem
source
stem cells
bone marrow
derived mesenchymal
Prior art date
Application number
CY20181100378T
Other languages
English (en)
Inventor
Saud A. Sadiq
Violane K. Harris
Original Assignee
Multiple Sclerosis Research Center Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Multiple Sclerosis Research Center Of New York filed Critical Multiple Sclerosis Research Center Of New York
Publication of CY1120115T1 publication Critical patent/CY1120115T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0622—Glial cells, e.g. astrocytes, oligodendrocytes; Schwann cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0623—Stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/08—Coculture with; Conditioned medium produced by cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
    • C12N2506/1346—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells
    • C12N2506/1353—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from mesenchymal stem cells from bone marrow mesenchymal stem cells (BM-MSC)

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Παρέχονται μέθοδοι για αγωγή και/ή μείωση της δριμύτητας πολλαπλής σκλήρυνσης σε έναν άνθρωπο, μέσω χορήγησης προερχόμενων από αυτόλογα μεσεγχυματικά αρχέγονα κύτταρα νευρικών προδρόμων. Επίσης περιγράφεται μια in vitro μέθοδος για διαφοροποίηση προερχόμενων από μεσεγχυματικά αρχέγονα κύτταρα τύπων νευρικών πρόδρομων ολιγοδενδρογλοιακών και νευρωνικών κυττάρων.
CY20181100378T 2006-11-03 2018-04-04 Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων CY1120115T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85651506P 2006-11-03 2006-11-03
PCT/US2007/023184 WO2008057443A2 (en) 2006-11-03 2007-11-02 Bone marrow-derived mesenchymal stem cells as a source of neural progenitors

Publications (1)

Publication Number Publication Date
CY1120115T1 true CY1120115T1 (el) 2018-12-12

Family

ID=39365076

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100378T CY1120115T1 (el) 2006-11-03 2018-04-04 Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων

Country Status (15)

Country Link
US (5) US8642331B2 (el)
EP (2) EP3031326A3 (el)
CA (1) CA2668200C (el)
CY (1) CY1120115T1 (el)
DK (1) DK2086332T3 (el)
ES (1) ES2663875T3 (el)
HR (1) HRP20180533T1 (el)
HU (1) HUE036745T2 (el)
LT (1) LT2086332T (el)
MX (1) MX2009004776A (el)
PL (1) PL2086332T3 (el)
PT (1) PT2086332T (el)
RS (1) RS57083B1 (el)
SI (1) SI2086332T1 (el)
WO (1) WO2008057443A2 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2086332T (lt) 2006-11-03 2018-04-25 Multiple Sclerosis Research Center Of New York Mezenchiminės kamieninės ląstelės, gautos iš kaulų čiulpų, kaip neuroninių pradininkų šaltinis
US9301975B2 (en) 2009-05-01 2016-04-05 Biocardia, Inc. Method of preparing autologous cells and method of use for therapy
US20120020931A1 (en) 2010-06-02 2012-01-26 Rutgers, The State University Of New Jersey Therapeutic encapsulated embryonic stem cells and mesenchymal stromal cells
EP2605765B1 (en) 2010-08-18 2019-05-08 Theresa Deisher Dexamethasone for use in treating osteoarthritis, liver failure, type-2 diabetes mellitus, stroke and parkinson's disease, in combination with stem cell treatment
EP2624845A4 (en) * 2010-10-08 2015-09-09 Mesoblast Internat S Rl REINFORCED MSC PREPARATIONS
WO2012070964A1 (ru) * 2010-11-22 2012-05-31 Farber Boris Slavinovich Модифицированные олигопептиды с противораковыми свойствами и способ их получения
EP3058063B1 (en) 2013-10-14 2018-06-06 Hadasit Medical Research Services and Development Ltd. Method of obtaining terminally differentiated neuronal lineages
WO2015143074A1 (en) * 2014-03-20 2015-09-24 University Of Southern California Brain cancer immunotherapy
WO2016168993A1 (en) 2015-04-22 2016-10-27 Innolife Co., Ltd. Methods of tissue repair and regeneration
JP2018517743A (ja) 2015-06-15 2018-07-05 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 多系統萎縮症を治療するための自家間葉系幹細胞の使用
CN108291207A (zh) 2015-10-08 2018-07-17 神经元治疗公司 神经前体细胞群体及其用途
CA3062123A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
WO2018211486A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
WO2021020666A1 (en) * 2019-07-26 2021-02-04 Brexogen Inc. Precursor cells of induced pluripotent stem cell-derived mesenchymal stem cells and method for preparing the same

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037719B1 (en) 1999-02-12 2006-05-02 Stemcells California, Inc. Enriched central nervous system stem cell and progenitor cell populations, and methods for identifying, isolating and enriching for such populations
US8017112B2 (en) * 1999-05-14 2011-09-13 Henry Ford Health System Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases
US20040208858A1 (en) * 2000-04-12 2004-10-21 Gihan Tennekoon Therapeutic uses for mesenchymal stromal cells
CA2465653C (en) * 2001-10-30 2013-10-08 Renomedix Institute Inc. Method for inducing differentiation of mesodermal stem cells, es cells, or immortalized mesodermal stem cells into neural cells
CN101243178A (zh) * 2005-06-16 2008-08-13 特拉维夫大学拉莫特有限公司 用于治疗cns疾病的分离细胞和包含这种细胞的细胞群
LT2086332T (lt) 2006-11-03 2018-04-25 Multiple Sclerosis Research Center Of New York Mezenchiminės kamieninės ląstelės, gautos iš kaulų čiulpų, kaip neuroninių pradininkų šaltinis

Also Published As

Publication number Publication date
CA2668200C (en) 2017-04-18
HUE036745T2 (hu) 2018-07-30
US20150118198A1 (en) 2015-04-30
HRP20180533T1 (hr) 2018-05-18
CA2668200A1 (en) 2008-05-15
WO2008057443A9 (en) 2008-07-17
SI2086332T1 (en) 2018-06-29
DK2086332T3 (en) 2018-04-16
EP2086332A4 (en) 2010-08-11
US20100166712A1 (en) 2010-07-01
EP3031326A2 (en) 2016-06-15
RS57083B1 (sr) 2018-06-29
US20140308745A1 (en) 2014-10-16
EP2086332A2 (en) 2009-08-12
MX2009004776A (es) 2009-07-14
WO2008057443A3 (en) 2008-11-20
EP2086332B1 (en) 2018-01-10
PT2086332T (pt) 2018-04-04
US9657268B2 (en) 2017-05-23
US20110236357A1 (en) 2011-09-29
US8642331B2 (en) 2014-02-04
WO2008057443A2 (en) 2008-05-15
LT2086332T (lt) 2018-04-25
PL2086332T3 (pl) 2018-07-31
EP3031326A3 (en) 2016-09-14
ES2663875T3 (es) 2018-04-17
US20150064145A1 (en) 2015-03-05
US9328329B2 (en) 2016-05-03

Similar Documents

Publication Publication Date Title
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
Migliario et al. Laser-induced osteoblast proliferation is mediated by ROS production
MY158100A (en) 6,9-disubstituted purine derivatives and their use for treating skin
PH12020552100A1 (en) Modified guide rnas for gene editing
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
ATE554725T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
ATE530142T1 (de) Chirurgische artikel zur behandlung von beckenerkrankungen
NZ602571A (en) Micrornas that regulate muscle cell proliferation and differentiation
CO6731080A2 (es) Compuestos de furo[3,2-d]pirimidina
BR112022011214A2 (pt) Rnas-guia modificados para edição de gene
MX353245B (es) Metodos para reprogramar células y sus usos.
CY1118073T1 (el) Συνθεσεις και μεθοδοι για την αυξηση της δρασης της τελομερασης
NZ569543A (en) Means and methods for influencing the stability of antibody producing cells
CL2011003346A1 (es) Compuestos derivados de 2,3-dihidro-5h-[1,3]tiazolo[3,2-a]pirimidin-5-ona, moduladores de pi3k; composicion farmaceutica; y uso para tratar una enfermedad de base inmunologica, cancer o enfermedad pulmonar en un paciente.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
UY31816A (es) Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112022001161A2 (pt) Formas cristalinas de 7-cloro-2-(4-(3-metoxiazetidin-1-il)ciclo-hexil)-2,4-dimetil-n-((6-metil-4-(metiltio)-2-óxo-1,2-di-hidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamida
HK1157814A1 (en) Materials and methods relating to cell based therapies
AU2016204146A1 (en) Methods of Increasing Neuronal Differentiation Using Antibodies to Lysophoshatidic Acid
ATE489628T1 (de) Galk1s als modifikatoren des pten/akt-wegs
AR059193A1 (es) Modulacion de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
BR112021015222A2 (pt) Métodos, sistemas e kits para tratamento de doença inflamatória de alvejamento de il18r1
PA8805901A1 (es) Nuevo uso medico de las sales de propionato de 3-(2,2,2-trimetilhidrazinio) para la profilaxis y el tratamiento de la aterosclerosis
AR082021A1 (es) Semuloparina para uso como un tratamiento antitrombotico en cirugia de reemplazamiento de cadera con disminucion de la incidencia de hemorragias clinicamente relevantes y hemorragias mayores